Full Year 2024 Results Key Financial Results Revenue: US$22.3m (down 12% from ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Capricor Therapeutics, Inc.’s CAPR share price has surged by 17.51%, which has investors questioning if this is right time to ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting. The ...

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw some unusual options trading on Thursday. Traders acquired ...

FDA accepts Capricor's Biologics License Application for priority review, advancing deramiocel for DMD cardiomyopathy.

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Wednesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

Shares of Capricor Therapeutics (CAPR) are trading up by about 13% on Thursday noon after the company announced ...